NDAORALTABLETPriority Review
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
16
Data completeness
5/8 — Partial
Priority Review
OXBRYTA (voxelotor) by Pfizer is hemoglobin s polymerization inhibitors [moa]. First approved in 2019.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXBRYTA (voxelotor) is an oral small-molecule hemoglobin S polymerization inhibitor approved in 2019 for sickle cell disease. It works by increasing hemoglobin's oxygen affinity, preventing polymerization of deoxygenated sickle hemoglobin and reducing hemolysis. The drug represents a mechanistically distinct approach to SCD management beyond pain crisis prevention.
$0.101BPart D
Peak11.1 years to LOEProduct is at peak commercial maturity with $101M in Part D spending; teams are focused on maximizing market penetration and patient access.
Mechanism of Action
Hemoglobin S Polymerization Inhibitors
Pharmacologic Class:
Hemoglobin S Polymerization Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
Started Oct 2023
6 enrolled
Sickle Cell Disease
Voxelotor Brain Oxygenation and Neurocognitive Study
Started Aug 2023
0Sickle Cell Disease
Voxelotor CYP and Transporter Cocktail Interaction Study
Started Apr 2023
44 enrolled
Sickle Cell Disease
Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor
Started Mar 2023
30 enrolled
Sickle Cell Disease
Voxelotor Neurocognitive Function Study
Started Jun 2022
1 enrolled
Sickle Cell Disease
Worked on OXBRYTA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.